• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 4. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

Introduction to 6-Chloro-5-difluoromethyl-nicotinic acid (CAS No. 1805304-08-8)

6-Chloro-5-difluoromethyl-nicotinic acid, identified by its Chemical Abstracts Service (CAS) number 1805304-08-8, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the nicotinic acid derivatives, a class of molecules known for their diverse biological activities and therapeutic potential. The structural features of 6-Chloro-5-difluoromethyl-nicotinic acid, particularly the presence of a chloro substituent at the 6-position and a difluoromethyl group at the 5-position of the nicotinic acid core, contribute to its unique chemical properties and biological interactions.

The significance of 6-Chloro-5-difluoromethyl-nicotinic acid lies in its utility as a key intermediate in the synthesis of various pharmacologically active agents. Nicotinic acid derivatives have been extensively studied for their roles in modulating metabolic pathways, particularly in the context of glucose and lipid metabolism. Recent advancements in drug discovery have highlighted the importance of structural modifications in nicotinic acid derivatives to enhance their efficacy and selectivity. The introduction of halogenated substituents, such as chlorine and fluorine, has been shown to improve the binding affinity and metabolic stability of these compounds, making them promising candidates for further development.

In recent years, 6-Chloro-5-difluoromethyl-nicotinic acid has been explored in several preclinical studies aimed at identifying novel therapeutic agents for metabolic disorders, including type 2 diabetes and hyperlipidemia. The compound’s ability to interact with specific enzymes and receptors has been investigated, revealing potential mechanisms through which it may exert its pharmacological effects. For instance, studies have suggested that modifications at the 5-position of the nicotinic acid ring can influence the compound’s ability to inhibit enzymes involved in fatty acid synthesis and cholesterol metabolism.

One of the most compelling aspects of 6-Chloro-5-difluoromethyl-nicotinic acid is its versatility as a building block for more complex drug molecules. Chemists have leveraged its reactive sites to develop derivatives with enhanced pharmacokinetic profiles and improved target specificity. The chloro substituent, in particular, provides a handle for further functionalization through nucleophilic substitution reactions, allowing for the introduction of additional pharmacophores. This flexibility has enabled researchers to design molecules with tailored biological activities, making 6-Chloro-5-difluoromethyl-nicotinic acid an invaluable asset in medicinal chemistry.

The synthesis of 6-Chloro-5-difluoromethyl-nicotinic acid typically involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Key synthetic strategies often include halogenation reactions at specific positions on the nicotinic acid backbone, followed by purification steps to isolate the desired product. Advances in synthetic methodologies have enabled more efficient production processes, reducing costs and improving scalability for industrial applications.

From a regulatory perspective, 6-Chloro-5-difluoromethyl-nicotinic acid is subject to standard guidelines governing the production and handling of pharmaceutical intermediates. Compliance with Good Manufacturing Practices (GMP) ensures that the compound is produced under controlled conditions that meet safety and quality standards. This adherence is crucial for ensuring consistency in its supply chain and facilitating its use in clinical trials and commercial drug development.

The future prospects for 6-Chloro-5-difluoromethyl-nicotinic acid are promising, with ongoing research exploring its potential applications beyond metabolic disorders. Studies are investigating its role in anti-inflammatory therapies and neuroprotective agents, leveraging its structural similarities to known bioactive compounds. The compound’s unique combination of chemical features makes it a compelling candidate for further exploration in drug discovery pipelines.

In conclusion, 6-Chloro-5-difluoromethyl-nicotinic acid (CAS No. 1805304-08-8) represents a significant advancement in pharmaceutical chemistry. Its structural characteristics, synthetic accessibility, and biological potential position it as a valuable tool for researchers developing novel therapeutic agents. As scientific understanding continues to evolve, it is likely that this compound will play an increasingly important role in addressing some of today’s most pressing medical challenges.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)